Valerie Olivier

Safety and efficacy of agomelatine in children and adolescents with major depressive disorder receiving psychosocial counselling: a double-blind, randomised, controlled, phase 3 trial in nine countries.

Journal: The lancet. Psychiatry

Published: April 08, 2021

Efficacy of Agomelatine 25-50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies.

Journal: Advances in therapy

Published: September 14, 2020

The safety of agomelatine in standard medical practice in depressed patients: A 26-week international multicentre cohort study.

Journal: Human psychopharmacology

Published: February 11, 2020

Effect of agomelatine 25-50 mg on functional outcomes in patients with major depressive disorder.

Journal: Journal of affective disorders

Published: February 16, 2018

12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder.

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Published: November 27, 2017

Discriminating between Anxious and Non-Anxious Subjects Using the Toronto Hospital Alertness Test.

Journal: Frontiers in psychiatry

Published: October 24, 2016

Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study.

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Published: September 21, 2016

Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study.

Journal: The Journal of clinical psychiatry

Published: February 18, 2013

The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study.

Journal: The Journal of clinical psychiatry

Published: October 29, 2012

Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study.

Journal: The Journal of clinical psychiatry

Published: October 28, 2011

Safety and efficacy of agomelatine in children and adolescents with major depressive disorder receiving psychosocial counselling: a double-blind, randomised, controlled, phase 3 trial in nine countries.

Safety and efficacy of agomelatine in children and adolescents with major depressive disorder receiving psychosocial counselling: a double-blind, randomised, controlled, phase 3 trial in nine countries.

Efficacy of Agomelatine 25-50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies.

Efficacy of Agomelatine 25-50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies.

The safety of agomelatine in standard medical practice in depressed patients: A 26-week international multicentre cohort study.

The safety of agomelatine in standard medical practice in depressed patients: A 26-week international multicentre cohort study.

Effect of agomelatine 25-50 mg on functional outcomes in patients with major depressive disorder.

Effect of agomelatine 25-50 mg on functional outcomes in patients with major depressive disorder.

12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder.

12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder.

Discriminating between Anxious and Non-Anxious Subjects Using the Toronto Hospital Alertness Test.

Discriminating between Anxious and Non-Anxious Subjects Using the Toronto Hospital Alertness Test.

Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study.

Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study.

Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study.

Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study.

The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study.

The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study.

Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study.

Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study.

Effect of agomelatine 25-50 mg on functional outcomes in patients with major depressive disorder.

Effect of agomelatine 25-50 mg on functional outcomes in patients with major depressive disorder.

12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder.

12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder.